Raymond James & Associates’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $1.12B | Buy |
9,874,714
+114,080
| +1% | +$13.6M | 0.68% | 21 |
|
|
2024
Q2 | $1.21B | Sell |
9,760,634
-36,592
| -0.4% | -$4.71M | 0.79% | 15 |
|
|
2024
Q1 | $1.29B | Buy |
9,797,226
+209,621
| +2% | +$25.8M | 0.88% | 14 |
|
|
2023
Q4 | $1.05B | Buy |
9,587,605
+178,132
| +2% | +$18.5M | 0.78% | 14 |
|
|
2023
Q3 | $969M | Buy |
9,409,473
+68,629
| +0.7% | +$7.4M | 0.81% | 14 |
|
|
2023
Q2 | $1.08B | Sell |
9,340,844
-123,674
| -1% | -$14M | 0.89% | 11 |
|
|
2023
Q1 | $1.01B | Sell |
9,464,518
-191,072
| -2% | -$20.6M | 0.87% | 9 |
|
|
2022
Q4 | $1.07B | Buy |
9,655,590
+621,130
| +7% | +$63.5M | 0.98% | 9 |
|
|
2022
Q3 | $778M | Buy |
9,034,460
+272,275
| +3% | +$24.3M | 0.79% | 14 |
|
|
2022
Q2 | $799M | Sell |
8,762,185
-137,864
| -2% | -$12.2M | 0.78% | 15 |
|
|
2022
Q1 | $730M | Buy |
8,900,049
+423,594
| +5% | +$33.4M | 0.62% | 23 |
|
|
2021
Q4 | $650M | Sell |
8,476,455
-217,138
| -2% | -$17.3M | 0.52% | 31 |
|
|
2021
Q3 | $653M | Buy |
8,693,593
+313,402
| +4% | +$23.8M | 0.59% | 24 |
|
|
2021
Q2 | $652M | Buy |
8,380,191
+423,821
| +5% | +$31.5M | 0.59% | 25 |
|
|
2021
Q1 | $585M | Buy |
7,956,370
+42,819
| +0.5% | +$3.16M | 0.59% | 25 |
|
|
2020
Q4 | $618M | Buy |
7,913,551
+288,340
| +4% | +$22.1M | 0.68% | 21 |
|
|
2020
Q3 | $604M | Buy |
7,625,211
+95,221
| +1% | +$7.46M | 0.75% | 18 |
|
|
2020
Q2 | $556M | Buy |
7,529,990
+467,077
| +7% | +$35.2M | 0.74% | 18 |
|
|
2020
Q1 | $519M | Buy |
7,062,913
+511,383
| +8% | +$40.2M | 0.82% | 15 |
|
|
2019
Q4 | $569M | Buy |
6,551,530
+285,644
| +5% | +$23.5M | 0.72% | 20 |
|
|
2019
Q3 | $503M | Buy |
6,265,886
+198,802
| +3% | +$15.9M | 0.7% | 18 |
|
|
2019
Q2 | $485M | Buy |
6,067,084
+216,570
| +4% | +$16.6M | 0.7% | 17 |
|
|
2019
Q1 | $464M | Buy |
5,850,514
+132,319
| +2% | +$9.9M | 0.71% | 18 |
|
|
2018
Q4 | $417M | Buy |
5,718,195
+150,816
| +3% | +$10.6M | 0.73% | 19 |
|
|
2018
Q3 | $377M | Buy |
5,567,379
+101,139
| +2% | +$6.44M | 0.58% | 24 |
|
|
2018
Q2 | $317M | Sell |
5,466,240
-540,378
| -9% | -$30.5M | 0.53% | 27 |
|
|
2018
Q1 | $312M | Buy |
6,006,618
+413,412
| +7% | +$22.3M | 0.56% | 22 |
|
|
2017
Q4 | $300M | Buy |
5,593,206
+67,801
| +1% | +$3.76M | 0.55% | 26 |
|
|
2017
Q3 | $338M | Buy |
5,525,405
+64,593
| +1% | +$3.92M | 0.68% | 17 |
|
|
2017
Q2 | $334M | Buy |
5,460,812
+9,318
| +0.2% | +$567K | 0.72% | 14 |
|
|
2017
Q1 | $331M | Buy |
5,451,494
+248,313
| +5% | +$15.1M | 0.77% | 12 |
|
|
2016
Q4 | $292M | Buy |
5,203,181
+460,518
| +10% | +$27M | 0.75% | 17 |
|
|
2016
Q3 | $282M | Buy |
4,742,663
+495,109
| +12% | +$29M | 0.77% | 15 |
|
|
2016
Q2 | $233M | Buy |
4,247,554
+433,130
| +11% | +$23.1M | 0.73% | 18 |
|
|
2016
Q1 | $193M | Buy |
3,814,424
+165,829
| +5% | +$8.12M | 0.65% | 19 |
|
|
2015
Q4 | $184M | Buy |
3,648,595
+37,711
| +1% | +$1.9M | 0.66% | 19 |
|
|
2015
Q3 | $170M | Buy |
3,610,884
+147,270
| +4% | +$7.82M | 0.69% | 16 |
|
|
2015
Q2 | $188M | Buy |
3,463,614
+98,153
| +3% | +$5.5M | 0.72% | 11 |
|
|
2015
Q1 | $185M | Buy |
3,365,461
+434,986
| +15% | +$24.6M | 0.81% | 10 |
|
|
2014
Q4 | $159M | Buy |
2,930,475
+556,668
| +23% | +$31M | 0.78% | 13 |
|
|
2014
Q3 | $134M | Buy |
2,373,807
+508,501
| +27% | +$28.6M | 0.77% | 12 |
|
|
2014
Q2 | $103M | Buy |
1,865,306
+20,717
| +1% | +$1.13M | 0.63% | 16 |
|
|
2014
Q1 | $99.9M | Sell |
1,844,589
-41,485
| -2% | -$2.15M | 0.69% | 14 |
|
|
2013
Q4 | $90.1M | Buy |
1,886,074
+102,051
| +6% | +$4.66M | 0.68% | 15 |
|
|
2013
Q3 | $81M | Buy |
1,784,023
+103,296
| +6% | +$4.72M | 0.7% | 14 |
|
|
2013
Q2 | $74.5M | Buy |
+1,680,727
| New | +$75.1M | 0.7% | 17 |
|
Other funds holding MRK
Raymond James & Associates's MRK Position: Q3 2024 in Review
Raymond James & Associates increased its Merck (MRK) stake by 1.2% in Q3 2024, buying an estimated $13.6M and bringing the position to 9,874,714 shares worth $1.12B. The position accounts for 0.68% of the portfolio, ranked #21.
Raymond James & Associates first reported a position in MRK in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.29B in Q1 2024. 3,489 funds tracked by Wall St. Rank hold MRK as of Q3 2024.
- Raymond James & Associates held 9,874,714 shares of Merck worth $1.12B as of Q3 2024.
- Raymond James & Associates bought 114,080 Merck shares in Q3 2024, an estimated $13.6M.
- Merck made up 0.68% of Raymond James & Associates's portfolio in Q3 2024, its #21 holding.
- Raymond James & Associates first reported a position in Merck in Q2 2013 and has held it in 46 quarters since.
- Raymond James & Associates's Merck position peaked at $1.29B in Q1 2024.
- 3,489 funds tracked by Wall St. Rank held Merck as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.